z-logo
open-access-imgOpen Access
Successful ruxolitinib administration for a patient with steroid‐refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review
Author(s) -
Tomomasa Dan,
Isoda Takeshi,
Mitsuiki Noriko,
Yamashita Motoi,
Morishita Aoi,
Tomoda Takahiro,
Okano Tsubasa,
Endo Akifumi,
Kamiya Takahiro,
Yanagimachi Masakatsu,
Imai Kohsuke,
Kanegane Hirokazu,
Takagi Masatoshi,
Morio Tomohiro
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5242
Subject(s) - medicine , ruxolitinib , hematopoietic stem cell transplantation , pneumonia , adverse effect , stem cell , cryptogenic organizing pneumonia , transplantation , complication , refractory (planetary science) , lung , intensive care medicine , bone marrow , physics , biology , astrobiology , myelofibrosis , genetics
Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were observed. Ruxolitinib may be an alternative choice for HSCT‐related IPS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here